Cibus, Inc. (CBUS)
| Market Cap | 114.42M +86.1% |
| Revenue (ttm) | 3.64M -14.6% |
| Net Income | -127.09M |
| EPS | -2.78 |
| Shares Out | 76.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 396,790 |
| Open | 1.450 |
| Previous Close | 1.450 |
| Day's Range | 1.400 - 1.510 |
| 52-Week Range | 1.090 - 4.191 |
| Beta | 1.93 |
| Analysts | Buy |
| Price Target | 9.00 (+500.0%) |
| Earnings Date | May 14, 2026 |
About CBUS
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus,... [Read more]
Financial Performance
In 2025, Cibus's revenue was $3.64 million, a decrease of -14.62% compared to the previous year's $4.26 million. Losses were -$127.09 million, -49.45% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for CBUS stock is "Buy." The 12-month stock price target is $9.0, which is an increase of 500.00% from the latest price.
News
Cibus Announces the Election of Thomas Urban to Board of Directors
SAN DIEGO, April 15, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies...
Cibus, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, April 08, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cibus , Inc. , (“ Cibus " or the "Company") ( NASDAQ : CBUS) investors that the firm has initiated an investigation into p...
Cibus, Inc. Announces Pricing of Public Offering of Class A Common Stock
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies...
Cibus, Inc. Announces Proposed Public Offering of Class A Common Stock and Pre-Funded Warrants
SAN DIEGO, March 25, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies...
Cibus Earnings Call Transcript: Q4 2025
2025 marked a transformative year with major regulatory wins, expanded commercial partnerships, and significant cost reductions. The rice and sustainable ingredients programs are advancing toward key revenue milestones, supported by a strengthened cash position and streamlined operations.
Cibus Reports Fourth Quarter Financial Results and Provides Business Update
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies, today ann...
Cibus to Report Fourth Quarter 2025 Financial Results on March 17, 2026 After the Market Close and Host Conference Call
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the ...
Cibus Partnering with The John Innes Centre for UK Government's Farming Innovation Programme Precision Breeding Initiative
Cibus to utilize proprietary Rapid Trait Development System™ to enable development of durable resistance to Light Leaf Spot disease, which has caused estimated yield losses of up to £300m in recent ye...
Cibus, Inc. Announces Pricing of $20.0 Million Public Offering of Class A Common Stock
SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies,...
Cibus, Inc. Announces Proposed Public Offering of Class A Common Stock
SAN DIEGO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies,...
Cibus and Interoc Advance Rice Commercialization Strategy for Herbicide-Tolerant Traits in Key Markets across Latin America
Nonbinding Letter of Intent (LOI) sets framework for potential 2027 market entry in Ecuador and Colombia, followed by expansion into Peru, Central America and the Caribbean Expected to build on succes...
Cibus Welcomes the Positive Conclusion of Trilogue Negotiations on New Genomic Techniques Legislation Between the European Parliament and Council
Political agreement on New Genomic Techniques (NGTs), including gene editing, advances a science-based path for plant breeding innovation and supports Cibus' plans to bring improved traits to European...
Cibus Earnings Call Transcript: Q3 2025
Commercial traction accelerated with seven RISE agreements and expansion into India, targeting over $200 million in potential annual royalties. Cost reductions improved the cash runway, and initial biofragrance revenues are expected in 2026, with major commercial launches set for 2027 and beyond.
Cibus Reports Third Quarter Financial Results and Provides Year-to-Date Business Update for 2025
With the addition of Centro Internacional de Agricultura Tropical (CIAT) in the quarter, Cibus now has 5 LATAM Rice customers as momentum continues toward achieving 2027 targeted initial LATAM Rice re...
Cibus Announces the Election of Craig Wichner to Board of Directors
Appointment underscores company's commitment to long-term shareholder value creation and sustained business growth Appointment underscores company's commitment to long-term shareholder value creation ...
Cibus to Report Third Quarter 2025 Financial Results on November 13, 2025 After the Market Close and Host Conference Call
SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the c...
Cibus Transcript: LD Micro Main Event XIX Investor Conference
The conference highlighted advances in gene editing for crop productivity, rapid trait development, and a royalty-based business model targeting major crops like rice, canola, and soybean. Supportive global regulations and strong partnerships position the company for significant growth by 2027.
Cibus and AgVayā Collaborate to Introduce Indian Rice Growers to New Solutions to Scale Crop Productivity Through Advanced Gene Editing
Collaboration aims to accelerate the adoption of advanced gene editing technologies in and deliver high-performance traits that support more sustainable and productive rice production in India Collabo...
Cibus Announces Positive Field Trial Results for Second-Generation Herbicide Tolerance (HT2) Edited Canola
Field testing confirms efficacy of HT2 trait in Canola under real-world conditions HT2 trait will be offered to potential seed licensing partners for introduction into commercial Canola seed products ...
Cibus Announces the Election of Kimberly A. Box to Board of Directors
Appointment strengthens governance and commercialization strategy expertise as Cibus continues preparations for launch of its advanced trait technologies delivering crop productivity and sustainabilit...
Cibus CEO to Highlight Gene Editing's Role in Building Resilient Agriculture at UN Climate Week 2025
SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specializing in the development and licensing of gene-edited plant traits, today ann...
Cibus Enters into Agreement with the Latin American Rice Hybrid Consortium to Provide Cibus' Herbicide Tolerance Trait
Cibus and Centro Internacional de Agricultura Tropical (CIAT) have entered into an agreement to introduce Cibus' proprietary herbicide tolerance trait into elite rice germplasm for Latin America Agree...
Cibus Earnings Call Transcript: Q2 2025
Focused execution on rice and biofragrance programs drove Q2 revenue growth and cost reductions, with initial biofragrance revenues expected in late 2025 and major rice trait launches in 2027–2028. Cash runway extends into Q2 2026, supported by a recent public offering and disciplined capital allocation.
Cibus Reports Second Quarter Financial Results and Provides Year-to-Date Business Update for 2025
Streamlining operational focus on Rice herbicide tolerance traits and partner-funded and/or supported programs, expected to reduce annual cash usage to approximately $30 million by 2026